01427nas a2200361   4500000000100000008004100001260001300042653003700055653003300092653001100125653002200136653001100158653001200169653001900181653000900200653003900209653001700248653004200265653002500307653002000332653002400352653003000376653001700406653002200423100001200445245007800457856005100535300001100586490000700597050001500604520043200619022001401051       2003                            d  c2003 Dec10aDose-Response Relationship, Drug10aDrug Administration Schedule10aFemale10aFollow-Up Studies10aHumans10aleprosy10aLong-Term Care10aMale10aPeripheral Nervous System Diseases10aPrednisolone10aRandomized Controlled Trials as Topic10aRecovery of Function10aRisk Assessment10aSensation Disorders10aSeverity of Illness Index10aTime Factors10aTreatment Outcome1 aNaafs B00aTreatment duration of reversal reaction: a reappraisal. Back to the past.  uhttps://leprosyreview.org/article/74/4/32-8336  a328-360 v74  aNAAFS 20033 a<p>In this paper, earlier data on the length of prednisolone treatment are re-examined. Based on those data and supported by the literature and the author's own observations, it can be concluded that type I leprosy reaction should be treated with prednisolone for a longer period than the 12 weeks, advised by the WHO. The paper also warns against silent nerve damage that may occur when prednisolone is discontinued early.</p>  a0305-7518